Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service mechanical circulatory support cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (146 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 113 | 21% |
| 2020 | 0 | 100 | 25% |
| 2021 | 0 | 106 | 29% |
| 2022 | 0 | 108 | 33% |
| 2023 | 0 | 96 | 37% |
| 2024 | 2 | 133 | 39% |
| 2025 from claims | – | 98 79–115 | 40% |
| 2026 forecast | – | 109 85–136 | 35% |
| 2027 forecast | – | 112 83–148 | 34% |
| 2028 forecast | – | 116 82–160 | 34% |
| 2029 forecast | – | 120 81–172 | 33% |
| 2030 forecast | – | 124 81–184 | 33% |
Percutaneous ventricular assist and intra-aortic balloon pump. Professional codes (what the surgeon bills): CPT 33990, 33991, 33995, 33967, 33970; the hospital bills MS-DRG 268, 269.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Hampshire; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 4 | 1,076−3%/yr | −3%/yr | 0.6 | 0% | 1,080 in 2030+0.1%/yr |
| Pennsylvania | 2 | 838−4.5%/yr | −4.5%/yr | 0.6 | 0% | 950 in 2030+2%/yr |
| Massachusetts | 3 | 596−1.7%/yr | −1.7%/yr | 0.6 | 0% | 560 in 2030−0.9%/yr |
| New Jersey | 1 | 507+0.1%/yr | +0.1%/yr | 0.5 | 0% | 870 in 2030+9.4%/yr |
| Connecticut | 1 | 152−4.1%/yr | −4.1%/yr | 0.5 | 0% | 40 in 2030−18%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 25 | 1,180−3.6%/yr | −3.6%/yr | 4.50.9× | 0% | 1,640 in 2030+5.7%/yr |
| Structural heart (TAVR, TEER) | 24 | 582+6.7%/yr | +6.7%/yr | 2.31.3× | 0% | 1,340 in 2030+15%/yr |
Mechanical circulatory support in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
No company payments named for these products in New Hampshire in 2025.
FDA, last 12 months: 48 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.